AAMU
NBIX icon

Amundi Asset Management US’s Neurocrine Biosciences NBIX Stock Holding History

Amundi Asset Management US’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$9.75M Buy
100,260
+9,151
+10% +$960K 0.01% 851
2020
Q4 		$8.73M Sell
91,109
-28,379
-24% -$2.74M 0.01% 848
2020
Q3 		$11.5M Buy
119,488
+6,615
+6% +$765K 0.01% 702
2020
Q2 		$13.8M Buy
112,873
+3,272
+3% +$362K 0.02% 610
2020
Q1 		$9.49M Buy
109,601
+14,334
+15% +$1.4M 0.02% 580
2019
Q4 		$10.2M Buy
95,267
+28,217
+42% +$2.95M 0.01% 742
2019
Q3 		$6.04M Sell
67,050
-33,866
-34% -$3.16M 0.01% 816
2019
Q2 		$8.52M Buy
+100,916
New +$8.29M 0.01% 821
2018
Q4 		– Sell
-67,900
Closed -$8.35M – 1647
2018
Q3 		$8.35M Sell
67,900
-1,400
-2% -$159K 0.01% 786
2018
Q2 		$6.81M Buy
69,300
+10,700
+18% +$958K 0.01% 834
2018
Q1 		$4.86M Buy
+58,600
New +$4.95M 0.01% 868
2017
Q4 		– Sell
-23,783
Closed -$1.46M – 1566
2017
Q3 		$1.46M Buy
+23,783
New +$1.25M ﹤0.01% 469
2017
Q1 		– Sell
-153,347
Closed -$5.93M – 551
2016
Q4 		$5.93M Sell
153,347
-3,818
-2% -$173K 0.02% 378
2016
Q3 		$7.96M Sell
157,165
-836
-0.5% -$41.6K 0.03% 349
2016
Q2 		$7.18M Sell
158,001
-35,025
-18% -$1.61M 0.03% 352
2016
Q1 		$7.63M Buy
193,026
+3,553
+2% +$141K 0.03% 336
2015
Q4 		$10.7M Buy
189,473
+72,801
+62% +$3.7M 0.04% 302
2015
Q3 		$4.64M Sell
116,672
-27,643
-19% -$1.34M 0.02% 435
2015
Q2 		$6.89M Sell
144,315
-49,556
-26% -$2.1M 0.03% 405
2015
Q1 		$7.7M Sell
193,871
-44,750
-19% -$1.6M 0.03% 384
2014
Q4 		$5.33M Sell
238,621
-265,317
-53% -$5.03M 0.02% 443
2014
Q3 		$7.9M Sell
503,938
-7,679
-2% -$115K 0.03% 373
2014
Q2 		$7.59M Buy
511,617
+77,103
+18% +$1.09M 0.03% 395
2014
Q1 		$7M Sell
434,514
-90,009
-17% -$1.54M 0.03% 400
2013
Q4 		$4.9M Buy
524,523
+50,037
+11% +$488K 0.02% 455
2013
Q3 		$5.37M Buy
474,486
+226,486
+91% +$3.11M 0.02% 445
2013
Q2 		$3.32M Buy
+248,000
New +$3.05M 0.01% 497

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Amundi Asset Management US's NBIX Position: Q1 2021 in Review

Amundi Asset Management US increased its Neurocrine Biosciences (NBIX) stake by 10% in Q1 2021, buying an estimated $960K and bringing the position to 100,260 shares worth $9.75M. The position accounts for 0.01% of the portfolio, ranked #851.

Amundi Asset Management US first reported a position in NBIX in Q2 2013 and has held it in 27 quarters since. The position peaked at $13.8M in Q2 2020. 420 funds tracked by Wall St. Rank hold NBIX as of Q1 2021.

  • Amundi Asset Management US held 100,260 shares of Neurocrine Biosciences worth $9.75M as of Q1 2021.
  • Amundi Asset Management US bought 9,151 Neurocrine Biosciences shares in Q1 2021, an estimated $960K.
  • Neurocrine Biosciences made up 0.01% of Amundi Asset Management US's portfolio in Q1 2021, its #851 holding.
  • Amundi Asset Management US first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 27 quarters since.
  • Amundi Asset Management US's Neurocrine Biosciences position peaked at $13.8M in Q2 2020.
  • 420 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.